Conventional clinical tests, including coagulation profiles (PT, APTT, etc.) and light transmission aggregometry (LTA) for platelet aggregation assessment, have prominent limitations. Routine coagulation profiles only detect levels of plasma coagulation factors in the absence of platelets, completely ignoring the central role of platelets in thrombosis and hemostasis. Traditional light transmission aggregometry merely observes platelet aggregation and fails to reflect the complete process wherein activated platelets release procoagulant substances to reinforce blood clots. The testing environment differs greatly from the actual in vivo coagulation environment of the human body, often leading to inconsistent test results versus patients’ real risks of bleeding or thrombosis.
ATEG coagulation-based platelet function testing uses whole blood to record changes during clot formation. This article discusses how the resulting curves and parameters are interpreted in platelet function research.
01
Platelets: The Core Force for Human Hemostasis and Thrombosis Formation
Most people only know that low platelet counts cause bleeding, yet they fail to understand that normal platelet counts do not guarantee intact platelet function. When blood vessel walls are damaged, human hemostasis proceeds in two major phases, with platelets serving as key participants throughout both stages.
In the primary hemostatic phase, platelets rapidly adhere to collagen at damaged blood vessels and recruit surrounding platelets to aggregate via the signaling molecules ADP and thromboxane A2, preliminarily plugging the vascular lesion. In the secondary hemostatic phase, activated platelets release two critical procoagulant factors (PF3 and PF4) stored in granules, enhancing coagulation strength at the molecular level.
PF3 Platelet Factor 3
Upon platelet activation, the cell membrane flips outward to expose phospholipids, forming a catalytic platform for coagulation reactions. This dramatically accelerates the conversion of prothrombin to thrombin, rapidly promoting fibrin production and laying a solid foundation for blood clots.
PF4 Platelet Factor 4
A cationic protein that neutralizes anticoagulants such as heparin and antithrombin in the blood, attenuating the body’s anticoagulant system. It further boosts blood coagulability, rendering blood clots firmer and less prone to detachment.
Common clinical antiplatelet drugs, including aspirin, clopidogrel, and ticagrelor, work by separately blocking the AA and ADP activation pathways. They inhibit platelet activation, reduce the release of PF3 and PF4, mitigate hypercoagulability, and prevent myocardial infarction, cerebral infarction, and in-stent thrombosis.
Platelet aggregation and clot strength describe different aspects of the coagulation process. The following section explains how ATEG records changes in clot strength in whole blood.
02
Principles of ATEG Coagulation-Based Platelet Testing
The ATEG platform includes modules for sampling, temperature-controlled incubation, mixing, and measurement. In the workflow discussed here, arachidonic acid (AA) and adenosine diphosphate (ADP) are used to activate separate platelet pathways. Sensors record changes in clot elasticity and produce curves with parameters including R, K, α angle, and MA.
When platelets are fully activated and release abundant PF3 and PF4, coagulation catalytic efficiency rises sharply. The R value (coagulation initiation time) and K value (fibrin formation speed) are markedly shortened, while the α angle widens, indicating faster blood clot generation. The maximum amplitude (MA) directly corresponds to overall blood clot strength: higher PF3 and PF4 release yields a larger MA value, stronger blood coagulability, and elevated thrombosis risk. Conversely, defective platelet function and inadequate procoagulant factor release prolong R and K values and lower MA, suggesting risks of spontaneous hemorrhage or postoperative bleeding.
The workflow includes three components:
Whole-Blood Clot Formation
ATEG uses temperature-controlled whole-blood samples to record changes during clot formation. The resulting curve reflects contributions from multiple blood components, including coagulation factors, fibrinogen, and platelets.
AA and ADP Pathway Measurements
The assay uses AA and ADP activation to assess pathway-specific platelet responses and records the resulting changes in clot strength.
Automated Testing and Reporting
The instrument automates sample mixing, incubation, activator addition, and curve acquisition. It reports the thromboelastography curve and its measured parameters.
03
Clinical Research Settings
Individualized Monitoring of Antiplatelet Medication
Patients with coronary heart disease, coronary stents, and intracranial aneurysm embolization generally require long-term dual antiplatelet therapy. Medication dosage control poses a major clinical challenge: insufficient drug efficacy leads to excessive platelet activation and massive PF3/PF4 release, easily triggering in-stent thrombosis, acute myocardial infarction, and cerebral infarction; overmedication strongly suppresses platelet function and reduces PF3/PF4 release, inducing fatal complications such as gastrointestinal and intracranial hemorrhage.
The article discusses AA and ADP pathway inhibition measurements in the context of aspirin and P2Y12 inhibitor monitoring. These measurements are interpreted alongside other clinical findings.
Assessment of Thrombosis Risk
Patients with hypertension, hyperlipidemia, atrial fibrillation, diabetes, prior myocardial infarction or cerebral infarction, long-term bed rest, or tumors all fall into high-thrombosis-risk groups. Platelets in these patients tend to remain persistently pre-activated, and minor stimulation can trigger massive PF3/PF4 release, maintaining chronic hypercoagulability that may lead to arterial or venous thrombosis at any time.
The article discusses how R, K, and MA measurements from whole-blood testing can be interpreted in studies of hypercoagulability.
Coagulation Assessment in Bleeding and Transfusion Settings
The article discusses R and MA values in the assessment of coagulation and platelet function in patients with bleeding symptoms. These findings are interpreted alongside other clinical and laboratory information.
The article also discusses the interpretation of clotting measurements alongside other laboratory findings in perioperative and transfusion settings.
04
Technical Summary and Industry Development Outlook
ATEG records changes in whole-blood clot formation and reports curve parameters. The platelet function workflow discussed here uses AA and ADP activation.
The article discusses research on perioperative coagulation, antiplatelet monitoring, thrombosis risk, and bleeding disorders.
Further multicenter studies could help define testing procedures, reference intervals, and interpretation criteria for specific patient groups.
中文